User:Mr. Ibrahem/Natalizumab

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis (MS) and Crohn's disease (CD). For MS it is used for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For CD it is used when other treatments are not effective. It is given by gradual injection into a vein every 4 weeks.

Common side effects include urinary tract infection, throat inflammation, headache, dizziness, nausea, joint pain and tiredness. Other side effects may include progressive multifocal leukoencephalopathy (PML), herpes encephalitis, liver problems, anaphylaxis, low platelets, and infection. It is a monoclonal antibody which attaches to a protein called α4β1 integrin on white blood cells, decreasing inflammation.

Natalizumab was approved for medical use in the United States in 2004 and Europe in 2006. In the United Kingdom it costs the NHS about £1,100 per dose as of 2021. In the United States this amount costs about 7,800 USD.